Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

SKYRIZI 90 MG / 1 ML

RISANKIZUMAB : 90 MG / 1 ML · DIN 02546922 · ABBVIE CORPORATION

Health Canada status: APPROVED

What is SKYRIZI?

SKYRIZI 90 MG / 1 ML contains RISANKIZUMAB : 90 MG / 1 ML. It is listed in the Health Canada Drug Product Database under DIN 02546922, held by ABBVIE CORPORATION, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as approved, status dated 05-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is SKYRIZI used for?

Moderate to severe plaque psoriasis; active psoriatic arthritis; moderately to severely active Crohn's disease; moderately to severely active ulcerative colitis.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02546922
Brand nameSKYRIZI
Generic / active ingredientRISANKIZUMAB : 90 MG / 1 ML
ManufacturerABBVIE CORPORATION
Strength90 MG / 1 ML
Dosage formSOLUTION
Route of administrationSUBCUTANEOUS
SchedulePrescription
ATC codeL04AC18 RIZANKIZUMAB
BiosimilarNo
Health Canada statusAPPROVED
Status date05-Apr-2024

How is it administered?

Psoriasis/PsA: 150mg SC at Week 0, 4, then every 12 weeks. Crohn’s: 600mg IV at Week 0, 4, 8, then 360mg SC at Week 12 and every 8 weeks. UC: 1200mg IV induction, then 180mg or 360mg SC every 8 weeks.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at 2 to 8°C. Protect from light. Do not freeze. Diluted IV solution can be stored at room temp for 8h or refrigerated for 20h.

How is it supplied?

150mg/mL pre-filled pen/syringe; 180mg/1.2mL or 360mg/2.4mL cartridge with on-body injector; 90mg/mL pre-filled syringe (4-pack); 600mg/10mL vial.

Contraindications

Hypersensitivity to risankizumab or to any ingredient in the formulation or component of the container.

Warnings and precautions

May increase risk of infections (e.g., TB, URTI). Evaluate for TB prior to therapy. Avoid live vaccines. Serious hypersensitivity reactions/anaphylaxis may occur.

What can be used instead?

Other Canadian products sharing ATC code L04AC18 RIZANKIZUMAB. 5 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
SKYRIZI150 MG / 1 MLSOLUTIONABBVIE CORPORATIONMARKETEDDIN 02519283
SKYRIZI150 MG / 1 MLSOLUTIONABBVIE CORPORATIONMARKETEDDIN 02519291
SKYRIZI180 MG / 1.2 MLSOLUTIONABBVIE CORPORATIONMARKETEDDIN 02552507
SKYRIZI360 MG / 2.4 MLSOLUTIONABBVIE CORPORATIONMARKETEDDIN 02532093
SKYRIZI60 MGSOLUTIONABBVIE CORPORATIONMARKETEDDIN 02532107
SKYRIZI75 MG / 0.83 MLSOLUTIONABBVIE CORPORATIONCANCELLED POST MARKETDIN 02487454

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for SKYRIZI

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for SKYRIZI

Health Canada Drug Product Database (DPD), DIN 02546922. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.